SAN MATEO, Calif.–(BUSINESS WIRE)–Model N, Inc. (NYSE: MODN), the leading provider of cloud revenue management solutions for life sciences and high tech companies, today announced that Jason Blessing, president and CEO, will present at the JMP Securities Technology Conference in San Francisco, CA.
This presentation is scheduled for Monday, February 24, 2020, at 10:00 a.m. PT or 1:00 p.m. ET. A live webcast of the presentation will be accessible from the investor relations page of the Model N website at https://investor.modeln.com/.
About Model N
Model N is a leading provider of cloud revenue management solutions for life sciences and high tech companies. Our software helps companies drive mission-critical business processes such as pricing, quoting, contracting, regulatory compliance, rebates and incentives. With deep industry expertise, Model N supports the complex business needs of the world’s leading brands in pharmaceutical, medical technology, semiconductor, and high tech manufacturing across more than 120 countries, including Johnson & Johnson, AstraZeneca, Novartis, Microchip Technology and ON Semiconductor. For more information, visit www.modeln.com.
Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.
Contacts
Investor Relations Contact:
Gwyn Lauber
Model N, Inc.
650-610-4998
investorrelations@modeln.com
Media Contact:
Laura Ruark
Bospar
laura@bospar.com
Recognition by TechRadar Pro at CES 2026 underscores the strategic rationale behind Mixie’s strategic investment…
DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the…
Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER,…
HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at…
Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib…
-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch…